NK-cell & CAR-NK therapy

01Overview and value chain

Markers: [EC: ATMP Regulation (EC No 1394/2007) | OECD: Bio-Pharmaceuticals | Regulator: FDA (USA), EMA (EU), NMPA (China)]

NK-cell therapy (Natural Killer) and CAR-NK use innate effector cells to kill tumors. Unlike autologous CAR-T, NK cells are allogeneic, “off-the-shelf”: donor- or iPSC-derived, with no GVHD risk and minimal CRS. CAR-NK carries a chimeric antigen receptor (e.g. anti-CD19 or NCG2D) for tumor-antigen recognition. The iPSC-NK platform (Fate Therapeutics) yields scalable, standardised batches from a single cell line. Early-clinical responses reach 60–80% in haematological cancers, with a better toxicity profile than CAR-T.

Key platforms of NK therapy:

1. CAR-NK (CAR-NK): NK with a CAR (anti-CD19, NKG2D) — directed cytotoxicity.
2. iPSC-NK (iPSC-derived NK): standardised NK from induced pluripotent stem cells — scale.
3. Cord-blood NK (Cord-blood NK): donor NK from umbilical-cord blood (Takeda/MD Anderson).
4. NK engagers (NK-cell Engagers): bispecifics linking NK to tumor (Affimed).

Sectoral value chain

[donor/iPSC line] ──> [NK manufacture + expansion] ──> [CAR transduction (optional)]
                                                              │
                                                  (cryopreservation / QC)
                                                              │
                                                              ▼
[patient] <─── [off-the-shelf infusion] <─── [allogeneic dose release]

Value chain levels

Cross-cutting technologies of the sector:

• iPSC platform (iPSC Platform): standardised, scalable NK batches from one line.
• Off-the-shelf: ready doses — no autologous-manufacturing delay (vs CAR-T).
• NK-cell engagers: bispecifics (Affimed) — link NK to tumor without a CAR.

02US

The US leads CAR-NK design on an iPSC base (Fate, Nkarta), with NCI support.

Fate Therapeutics, Nkarta, NCI funding

• Fate Therapeutics: iPSC-NK platform — standard batches from a single line.
• Nkarta: NKX101 (NKG2D CAR-NK) — phase I in acute myeloid leukaemia.
• NCI: grants for fundamental and translational NK research.

03CN

China is rapidly adopting CAR-NK in solid and haematological cancer trials.

Clinical scale-up, NMPA pathway, domestic platforms

• Clinical experience: CAR-NK in hepatocellular carcinoma and lymphomas.
• Domestic platforms: local CAR-NK developers under NMPA.
• NMPA: accelerated pathways for strategic cell-therapy candidates.

04EU

The EU is strong in allogeneic platforms and NK-cell engagers.

Affimed engagers, EMA ATMP, academic NK programs

• Affimed (Germany): bispecific NK-cell engagers (ICE®) — link NK to tumor.
• EMA ATMP: allogeneic NK classified as ATMP; strict donor oversight.
• Academic programs: university NK protocols (Germany, Netherlands).

05Leading companies and research institutes

06Tech stack and innovations

The stack rests on iPSC-NK, off-the-shelf logistics and engagers.

1. iPSC-NK (iPSC-derived NK):
   • standardised NK from a single iPSC line — scalable batches.
2. Off-the-shelf:
   • cryobanked ready doses — infusion without autologous-manufacturing delay.
3. NK-cell engagers:
   • bispecific molecules (Affimed ICE®) link NK to tumor without engineering the cell.

07Value chains and production pipelines

Allogeneic CAR-NK manufacturing pipeline (ATMP / cGMP)

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Source (iPSC/cord)     │ ───> │ 2. NK expansion (14–21 d) │
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Fill & cryopreservation│ <─── │ 3. CAR transduction (opt.)│
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Release ready dose     │ ───> │ 6. Infusion (off-the-shelf)│
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Cell source

An iPSC line or donor umbilical-cord blood as the starting material.

Stage 2: NK expansion

NK differentiation/expansion with cytokines (IL-2, IL-15) over 14–21 days.

Stage 3: CAR transduction (optional)

Lentiviral CAR transduction (anti-CD19/NKG2D) for CAR-NK.

Stage 4: Fill & cryopreservation

Filling into doses, cryopreservation of the ready allogeneic product.

Stage 5: Dose release

Quality control (sterility, viability, potency); release of the ready dose.

Stage 6: Infusion

Thaw and infusion to the patient (off-the-shelf, often without deep lymphodepletion); response and NK-persistence monitoring.